Peptide Biomarkers BNP and Proadrenomedullin Predict Heart Death for at Least 15 Years
Six plasma biomarkers including BNP and proadrenomedullin predicted cardiovascular death for at least 15 years in 7,745 patients with chronic coronary heart disease, with associations sustained well beyond initial measurement.
Quick Facts
What This Study Found
All 6 biomarkers — BNP, troponin I, cystatin-C, CRP, D-dimer, and midregional proadrenomedullin — were significantly associated with cardiovascular death (n=1,903) both during the randomized trial period and for 10 additional years after trial completion (each p<0.001). Associations were sustained for at least 15 years total.
Key Numbers
7,745 patients from the LIPID trial. Biomarkers measured: BNP, troponin I, cystatin-C, and C-reactive protein.
How They Did This
Cohort study of 7,745 patients from the LIPID trial (Long-Term Intervention with Pravastatin in Ischemic Disease). Biomarkers measured at baseline and 1 year. Landmark analyses from 1 year evaluated discrimination for cardiovascular death during the next 5 years of the trial and 10 additional years of follow-up.
Why This Research Matters
Most biomarker studies only assess short-term prediction. Finding that peptide biomarkers like BNP and proadrenomedullin remain predictive for 15+ years suggests they capture deep, stable aspects of cardiovascular disease that don't fluctuate quickly. This has implications for long-term risk stratification and treatment decisions in coronary heart disease patients.
The Bigger Picture
This study demonstrates that a single set of biomarker measurements can inform cardiovascular risk for over a decade. The peptide biomarkers BNP and proadrenomedullin are particularly interesting because they reflect cardiac and vascular stress that may drive long-term disease progression. This supports the concept of multi-biomarker risk panels for personalized cardiovascular medicine.
What This Study Doesn't Tell Us
The LIPID trial enrolled patients in the 1990s, and cardiovascular management has evolved significantly since then. Biomarker associations may differ with modern treatments. The study didn't assess whether serial measurements improve prediction over single measurements. Observational analysis from a statin trial — cannot establish whether biomarker-guided treatment improves outcomes.
Questions This Raises
- ?Would biomarker-guided intensification of therapy in high-risk patients improve long-term cardiovascular outcomes?
- ?Do BNP and proadrenomedullin levels change with contemporary cardiovascular treatments in ways that affect their long-term predictive value?
Trust & Context
- Key Stat:
- 15+ years predictive All six biomarkers including the peptides BNP and proadrenomedullin maintained statistically significant prediction of cardiovascular death for at least 15 years after measurement (p<0.001)
- Evidence Grade:
- Strong evidence from a large, well-characterized clinical trial cohort (LIPID) with exceptionally long follow-up. Published in JAHA, a major cardiovascular journal.
- Study Age:
- Published in 2024, analyzing data from the LIPID trial (patients enrolled in the 1990s) with extended follow-up through the 2010s.
- Original Title:
- Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart Disease.
- Published In:
- Journal of the American Heart Association, 13(21), e034367 (2024)
- Authors:
- Stewart, Ralph A H, Robledo, Kristy P, Tonkin, Andrew M, Keech, Anthony, Kritharides, Leonard, Marschner, Ian, Janus, Edward, Thompson, Peter L, Watts, Gerald F, Zeller, Tanja, White, Harvey D, Simes, John
- Database ID:
- RPEP-09324
Evidence Hierarchy
Frequently Asked Questions
What is BNP and why does it predict heart problems?
BNP (B-type natriuretic peptide) is a hormone released by the heart when it's under stress — particularly when the ventricles are stretched. Higher BNP levels indicate the heart is working harder than it should. The fact that a single BNP measurement predicts death for 15+ years suggests it captures fundamental aspects of cardiac disease severity.
Should I ask my doctor for these biomarker tests?
BNP and troponin are already routinely measured in many cardiac patients. This study suggests that these results have long-term prognostic value beyond their immediate clinical use. If you have coronary heart disease, your doctors likely already use some of these markers for risk assessment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09324APA
Stewart, Ralph A H; Robledo, Kristy P; Tonkin, Andrew M; Keech, Anthony; Kritharides, Leonard; Marschner, Ian; Janus, Edward; Thompson, Peter L; Watts, Gerald F; Zeller, Tanja; White, Harvey D; Simes, John. (2024). Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart Disease.. Journal of the American Heart Association, 13(21), e034367. https://doi.org/10.1161/JAHA.123.034367
MLA
Stewart, Ralph A H, et al. "Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart Disease.." Journal of the American Heart Association, 2024. https://doi.org/10.1161/JAHA.123.034367
RethinkPeptides
RethinkPeptides Research Database. "Plasma Protein Biomarkers and Long-Term Cardiovascular Morta..." RPEP-09324. Retrieved from https://rethinkpeptides.com/research/stewart-2024-plasma-protein-biomarkers-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.